Press Detail





Biotest AG: Cooperation secures additional plasma protein capacity

Biotest AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Cooperation secures additional plasma protein capacity 

- Biotest agrees increased utilisation of CAF-DCF fractionation capacity 
- Agreement to run for ten years
- Annual Biotest capacity now rises to 1.4 million litres

Dreieich, 21 January 2009. Biotest has considerably expanded its plasma
fractionation capacity and broadened its basis for future growth by signing
a further cooperation agreement with the Belgium organisation CAF-DCF.
Under the ten-year agreement, Biotest will fractionate several hundred
thousand litres of blood plasma in CAF-DCF’s facilities in Brussels each
year. Coupled with the expansion of Biotest’s own production plant in Boca
Raton (USA) which is set for completion by the end of 2009, this increases
Biotest’s annual plasma fractionation capacity to around 1.4 million
litres.

Biotest has its own state-of-the-art fractionation plant in Dreieich and is
currently investing in the expansion of the facility at its subsidiary
Biotest Pharmaceuticals Corp. in Boca Raton, USA. In tandem with this, the
company is also expanding its purification facility for immunoglobulins in
the USA. This too should be complete by the end of 2009 and will increase
the annual capacity to 5.5 tonnes.

'The capacity increase strengthens our position as one of the leading
producers of plasma proteins worldwide,' said Chairman of the Management
Board of Biotest AG, Professor Dr. Gregor Schulz, commenting on the new
agreement with CAF-DCF. 'It is also the start of a new chapter in the
history of our existing 20-year cooperation.'

As a national manufacturer, CAF-DCF is responsible for supplying the
Belgian market with plasma proteins. The organisation’s shareholders are
the Belgian Red Cross, the Dutch foundation Sanquin and LFB, a state-owned
French company.

The plasma fractionation process separates human blood plasma into its
individual proteins (fractions). These form the raw materials for the
production of immunoglobulins and albumins, which are used in immunotherapy
and emergency medicine, as well as drugs to treat the blood disease
haemophilia.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,950
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's S-DAX.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth, 
Tel: +49 (0) 6103 801-520, 
e-mail: michael_ramroth@biotest.de
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 
21.01.2009  Financial News transmitted by DGAP
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Deutschland
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------